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Abstract
Background: Polymorphonuclear neutrophils (PMN) play a key role in host defences against invading microorganisms but
can also potentiate detrimental inflammatory reactions in case of excessive or misdirected responses. Intravenous
immunoglobulins (IVIg) are used to treat patients with immune deficiencies and, at higher doses, in autoimmune, allergic
and systemic inflammatory disorders.
Methodology/Principal Findings: We used flow cytometry to examine the effects of IVIg on PMN functions and survival,
using whole-blood conditions in order to avoid artifacts due to isolation procedures. IVIg at low concentrations induced
PMN activation, as reflected by decreased L-selectin and increased CD11b expression at the PMN surface, oxidative burst
enhancement, and prolonged cell survival. In contrast, IVIg at higher concentrations inhibited LPS-induced CD11b
degranulation and oxidative burst priming, and counteracted LPS-induced PMN lifespan prolongation.
Conclusions/Significance: IVIg appears to have differential, concentration-dependent effects on PMN, possibly supporting
the use of IVIg as either an anti-microbial or an anti-inflammatory agent.
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Introduction
Intravenous immunoglobulin (IVIg) is a therapeutic preparation
of normal human polyclonal IgG derived from pooled plasma
from a large number of healthy donors. Initially used as
replacement therapy for patients with primary and secondary
immune deficiencies, IVIg is now also widely used for the
treatment of a variety of autoimmune, allergic and systemic
inflammatory disorders, at high immunomodulatory doses
[1,2,3,4,5,6,7]. The ability of exogenous IVIg to prevent infections
in immunodeficient patients has been attributed to neutralization
of pathogens and bacterial toxins by specific antibodies. High-dose
IVIg is known to dampen the activity of dendritic cells,
lymphocytes, endothelial cells, monocytes and macrophages, and
to modulate cytokine synthesis and the complement system
[8,9,10,11]. However, a more precise understanding of the
mechanisms by which IVIg exerts its therapeutic effects is needed
for more rational use of this drug.
Polymorphonuclear neutrophils (PMN) are key components of
the first line of defense against invading microorganisms. In
response to pathogens, blood PMN rapidly migrate to inflamed
tissues, where their activation triggers microbicidal mechanisms
such as release of proteolytic enzymes and antimicrobial peptides,
and rapid production of reactive oxygen species (ROS), in the so-
called oxidative burst. This process is critical for bacterial killing
but can also cause severe bystander tissue injury if excessive or
inappropriate [12]. After bacterial killing, PMN die by apoptosis
and are then recognized and phagocytozed by macrophages [13].
PMN are usually short-lived immune cells, but prolongation of
their life span is critical for their tissue accumulation and pathogen
destruction [14]. Inappropriate PMN survival and persistence at
sites of inflammation can lead to the release of cytotoxic contents
into the extracellular environment, which may contribute to the
pathophysiology of chronic inflammatory and allergic diseases
[15,16,17].
The few published studies on the effects of IVIg on PMN
yielded conflicting results. Some authors report that IVIg alone
triggers PMN degranulation [18] while others describe an increase
in apoptotic PMN [19], which exhibit lower pro-inflammatory
activity [20]. It has been also suggested that IVIg may act as an
immunomodulator, inhibiting stimulus-induced PMN degranula-
tion [21] and survival [22]. However, Jarius et al reported a
priming effect of IVIg on the PMN oxidative burst in response to
TNF [23]. Importantly, most of these studies used PMN isolated
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Figure 1. IVIg at low concentrations activates PMN functions. Panels A, B, C and D: Effect of IVIg and F(ab9)2 fragments on adhesion molecule
expression at the PMN surface. Whole-blood samples (500 ml) were incubated in a water bath with gentle horizontal agitation at 37uC for 45 min with
PBS, HSA (1 or 25 mg/ml), or IVIg (1–25 mg/ml) (panel A, C) or equimolar concentrations of F(ab9)2 fragments (panel B, D). LPS (10 ng/ml, 45 min) was
used as a positive control. Samples were then stained with PE-anti-human CD11b or anti-L-selectin at 4uC for 30 min. Samples stained with anti-L-
selectin were washed with ice-cold PBS and incubated at 4uC for 30 min with FITC-goat anti-mouse. Then, erythrocytes were lysed with FACS lysing
solution and white blood cells were resuspended in 1% paraformaldehyde-PBS and analysed by flow cytometry. Nonspecific Ab binding was
determined on cells incubated with the same concentrations of an irrelevant Ab of the same isotype. Results are expressed as mean fluorescence
intensity (MFI). Values are means 6 sem (n= 6). * Significantly different from sample incubated with PBS (p,0.05). Panels E and F: Effect of IVIg and
F(ab9)2 fragments on the PMN oxidative burst in response to formyl peptides. Whole-blood samples (500 ml) were pre-treated with hydroethidine
(1500 ng/ml) for 15 min in a water bath with gentle horizontal agitation at 37uC. The samples were then incubated at 37uC for 45 min with PBS, HSA
(1 or 25 mg/ml), or IVIg (1–25 mg/ml) (panel E) or equimolar concentrations of F(ab9)2 (panel F) before stimulation with fMLP (10
26 M) for 5 min. A
sample incubated with LPS (10 ng/ml, 45 min) then with fMLP (1026 M, 5 min) was used as a positive control. Erythrocytes were lysed with FACS
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from their blood environment by various procedures that may
differently modulate cell responses [24,25].
The aim of this study was to re-examine the effect of IVIg on
key PMN functional characteristics, including adhesion molecule
expression, ROS production and survival, using resting and LPS-
stimulated PMN in whole-blood conditions in order to minimize
activation due to isolation procedures, an approach that we have
previously validated [26,27].
Results
IVIg at low concentrations enhances PMN activation
One of the main steps in PMN migration from the bloodstream
to an inflammatory site is the modulation of adhesion molecule
expression on both PMN and endothelial cells. In particular,
stimulus-induced shedding of L-selectin (CD62L), followed by
increased expression of the b2 integrin CD11b/CD18, is a major
mechanism underlying transendothelial migration [28]. IVIg is
used at two distinct dose regimens in clinical practice: in primary
and secondary immune deficiencies, IVIg is administered as a
substitutive agent at 400–500 mg/kg body weight whereas in
autoimmune and inflammatory conditions, IVIg is given at 1 g/kg
body weight. Accordingly, in the in vitro studies, these doses
correspond to 1–5 mg/ml or 25 mg/ml [29]. As shown in
Figure 1A and C, treatment of whole blood with IVIg at low
concentrations (1–5 mg/ml) reduced CD62L expression and
enhanced CD11b expression at the PMN surface, as compared
to the PBS control.
We have previously reported that, in whole blood, a single
stimulus gives rise to minimal ROS production by PMN [30]. We
therefore studied the effect of IVIg on the oxidative burst in
response to bacterial formyl peptides (fMLP). Pretreatment of
whole blood with IVIg at low concentrations followed by fMLP
stimulation significantly increased ROS production as compared
to fMLP alone (Figure 1E).
Similar results were obtained with equimolar amounts of F(ab9)2
fragments derived from IVIg (Fig. 1B, D, F), whereas no effect was
observed with equimolar amounts of Fc fragments (not shown).
HSA, used as an irrelevant protein, did not exert any significant
effect on the expression of PMN adhesion molecules and ROS
production at 1 and 25 mg/ml (Figure 1A, 1C, 1E) as well as at all
the other doses tested (5, 10, 15 and 20 mg/ml) (not shown).
IVIg at low concentrations delays PMN apoptosis
Bloodstream PMN have a short half-life, dying mainly by
apoptosis [31]. Prolongation of their lifespan is critical for efficient
pathogen destruction. We therefore investigated the effect of IVIg
on PMN apoptosis. Whole blood PMN cultured at 37uC died
rapidly by apoptosis, about 50% of cells being annexin V+ after
20 h. As previously reported [26], apoptosis was accelerated by
cycloheximide (10 mg/ml) and delayed by LPS (10 ng/ml). The
percentage of apoptotic cells in whole-blood samples incubated
with intact IVIg or F(ab9)2 fragments was significantly lower than
in the PBS control (Figure 2C and D). This anti-apoptotic effect
appears as soon as 8 hours and was not observed with IVIg-
derived Fc fragments (not shown). HSA did not exert any
significant effect on PMN apoptosis at 1 and 25 mg/ml
(Figure 2C) as well as at all the other doses tested (5, 10, 15 and
20 mg/ml) (not shown).
IVIg counteracts LPS-induced PMN activation and
survival
We then explored the capacity of IVIg to modulate PMN
responses to LPS, used as a pro-inflammatory stimulus. Both
CD11b expression at the PMN surface and ROS production
were significantly lower in samples incubated with LPS+IVIg at
high concentrations (15–25 mg/ml) than in samples incubated
with LPS alone (Figure 3C and E). In addition, IVIg significantly
inhibited LPS-induced PMN survival (Figure 4A). Similar results
on PMN lifespan were also obtained with other TLR ligands
such as TLR1/2 or TLR7/8 ligands (not shown). Fc fragments
had no significant effect on LPS-treated PMN (not shown), while
F(ab9)2 fragments countered LPS-induced modulations
(Figure 3D and F, and Figure 4B) more efficiently than IVIg.
In particular, F(ab9)2 fragments had a pro-apoptotic effect on
LPS-stimulated PMN.
To determine whether this effect was due to the presence of
auto-antibodies to sialic acid-binding Ig-like lectin 9 (Siglec-9) in
the IVIg preparation [19,32], we tested the effect of anti-Siglec-9-
depleted IVIg on LPS-induced PMN survival. In keeping with
previous data obtained with isolated PMN treated with GM-CSF
[19,33], we found that the death-inducing effect of IVIg in the
presence of LPS was totally abolished when anti-Siglec-9-depleted
IVIg was used (not shown).
Discussion
It is important to note that we analyzed PMN functions and
apoptosis by flow cytometry in whole-blood conditions, whereas
previous studies used isolated PMN. Indeed, PMN isolation
procedures have been reported to alter PMN responses
[24,25,26]. In addition, interactions between cellular elements
have been reported to be important for maintaining PMN
viability [34].
Our results show that low concentrations of IVIg, as well as
F(ab9)2 fragments, induce PMN activation, as reflected by
decreased L-selectin expression, increased CD11b/CD18 adhe-
sion molecule expression, and enhanced ROS production. These
effects may be related to ANCA-like antibodies reported to be
present in IVIg preparations [23]. Further, it is possible that
IVIG at higher concentrations trigger inhibitory signalling
pathways as has been demonstrated in the case of dendritic cells,
B and T lymphocytes [9]. Using whole-blood PMN, we found
that IVIg-induced PMN activation is also associated with
prolonged PMN survival. This anti-apoptotic effect may be due
to natural anti-Fas antibodies directed against the CH11 epitope
leading to an antagonist effect, although it has been shown that
IVIg contains both pro-apoptotic and anti-apoptotic anti-Fas
antibodies [35]. On the contrary, it has been previously reported
that IVIg alone induces PMN apoptosis [19,33]. These
discrepancies may be related to differences in antagonist and
agonists anti-Fas activities reported in various IVIg preparations
[36]. While this anti-apoptotic effect was not observed with Fc
fragments, the involvement of FccRII and FccRIII cannot be
ruled out.
Immunoglobulin replacement therapy significantly reduces the
incidence of lower airway infections and pneumonia in patients
with primary immunodeficiencies [37]. Although IVIg is known to
contain antibodies against various pathogens [38,39], its beneficial
effects might not be due solely to pathogen neutralization. Natural
lysing solution and white blood cells were resuspended in 1% paraformaldehyde-PBS. Samples were analysed by flow cytometry. Results are
expressed as mean fluorescence intensity (MFI). Values are means 6 sem (n= 3). * Significantly different from sample incubated with fMLP (p,0.05).
doi:10.1371/journal.pone.0026469.g001
Modulation of PMN Functions by IVIg
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26469
Figure 2. IVIg at low concentrations delays PMN apoptosis. Whole-blood samples (500 ml) were incubated in 24-well tissue culture plates at
37uC for 20 h with 5% CO2 with PBS, HSA (1 or 25 mg/ml), or IVIg (1–25 mg/ml) (Panel C) or equimolar concentrations of F(ab9)2 (Panel D). Cycloheximide
(CHX) (10 mg/ml) and LPS (10 ng/ml) were used as proapoptotic and antiapoptotic controls, respectively. Samples (100 ml) were then washed twice in
PBS, incubated at 4uC with APC-anti-CD15 for 15 min, and stained with FITC-annexin V for 15 min. After dilution in PBS (500 ml), the samples were
incubated with 7-AAD for 15 minutes at room temperature and analysed immediately by flow cytometry as described in Materials and Methods. Anti-
CD15 fluorescence was used to identify PMN as CD15+ cells and to gate out other cells, erythrocytes, and debris. A gate was drawn around the PMN
population (Panel A). Fluorescence analysis was performed on this gate (Panel B). The combination of FITC-annexin V and 7-AAD was used to distinguish
early apoptotic cells (annexin V+/7-AAD2), from late apoptotic cells (annexin V+/7-AAD+), necrotic cells (annexin V2/7-AAD+) and viable cells (unstained)
after incubation with PBS, CHX, LPS or IVIg (1–25 mg/ml). Results are expressed as the percentage of total apoptotic cells (early and late apoptotic cells).
The proportion of necrotic cells was always below 2%. Values aremeans6 sem (n= 3). * Significantly different from sample incubated with PBS (p,0.05).
doi:10.1371/journal.pone.0026469.g002
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antibodies present in IVIg enhance opsonization and thus promote
phagocytosis and antibody-mediated cytotoxicity [40]. Neutrophils
are the first cells to be recruited to sites of infection in response to a
variety of inflammatory stimuli, and protect the host by engulfing,
killing and digesting infectious agents. The PMN activation and
lifespan prolongation observed here with low concentrations of
IVIg could enhance defenses against microbial pathogens in vivo.
In addition, inhibition of PMN apoptosis by IVIg may contribute
to reducing the incidence and severity of neutropenia, which is a
feature of several antibody deficiencies [41].
Contrary to low concentrations, high concentrations of IVIg
inhibited the LPS-induced increase in CD11b expression and
ROS production by PMN, as well as the LPS-induced delay in
PMN apoptosis. In keeping with previous data obtained with
isolated PMN treated with GM-CSF [19] [33], PMN apoptosis
was not delayed by anti-Siglec-9 depleted IVIg. This result
emphasizes the hypothesis that anti-Siglec-9 Abs contained in
IVIg preparation exert a pro-apoptotic effect under certain
inflammatory conditions that sensitize PMN towards the
induction of apoptosis [42] [43]. Siglec receptors belong to the
Ig supergene family and are characterized by the presence of an
N-terminal V-set domain that binds sialic acid [44]. These
receptors are predominantly expressed on cells of the innate and
adaptative immune system, in a cell-type-restricted and differen-
tiation-dependent manner [44]. For instance, Siglec-9 is predom-
inantly expressed on monocytes and PMN [45]. It has been
clearly established that Siglec-9 ligation triggers PMN apoptosis
through caspase-dependent and -independent pathways [19]
[46]. Engagement of Siglec-9 has also been reported to dampen
neutrophil responses, including the oxidative burst [47]. Finally,
neutralization of LPS by anti-LPS antibodies within IVIg
preparations cannot be ruled out. Presence of anti-LPS antibodies
in IVIg has been previously documented [48]. However, we have
also shown that IVIg could block human dendritic cell
maturation when cells are pre-exposed to LPS followed by
treatment with IVIg [48]. Therefore, in addition to direct
neutralization of LPS, other mechanisms of counteracting its
effect on PMN activation and survival (such as blocking the
interaction of LPS with TLR-4 and associated molecules, and
inhibiting down-stream signaling) might be implicated in IVIg-
mediated regulation of PMN functions. Furthermore, the pro-
apoptotic effect of IVIg on whole-blood PMN may also be related
to IVIg-induced down-modulation of anti-apoptotic cytokines by
activated monocytes [9].
Figure 3. IVIg at high concentrations inhibits PMN responses to LPS stimulation. Panels A, B, C and D: Effect of IVIg and F(ab9)2 fragments
on LPS modulation of adhesion molecule expression at the PMN surface. Whole-blood samples were incubated at 37uC for 15 min with PBS, IVIg (1–
25 mg/ml) (panel A, C) or equimolar concentrations of F(ab9)2 (panel B, D) and then with LPS (10 ng/ml) for 30 min. Samples were then stained with
PE-anti-human CD11b or anti-L-selectin as described in the legend of Figure 1. Results are expressed as mean fluorescence intensity (MFI). Values are
means 6 sem (n= 3). u Significantly different from sample incubated with LPS (p,0.05). Panels E and F: Effect of IVIg and F(ab9)2 fragments on LPS
priming of the PMN oxidative burst in response to formyl peptides. Whole-blood samples (500 ml) were pre-treated with hydroethidine HE and
incubated at 37uC for 15 min with PBS, IVIg (1–25 mg/ml) (panel E) or equimolar concentrations of F(ab9)2 (panel F). Samples were then incubated
with LPS and fMLP as described in the legend of Figure 1. Results are expressed as mean fluorescence intensity (MFI). Values are means6 sem (n= 3).
* Significantly different from sample incubated with LPS+fMLP (p,0.05).
doi:10.1371/journal.pone.0026469.g003
Figure 4. IVIg at high concentrations inhibits the LPS-induced prolongation of PMN survival. Whole-blood samples (500 ml) were
incubated in 24-well tissue culture plates at 37uC with 5% CO2 with PBS, IVIg (1–25 mg/ml) (panel A) or equimolar concentrations of F(ab9)2 (panel B)
for 15 min and then with LPS (10 ng/ml) for 20 h. Samples were then stained with annexin V and 7-AAD as described in the legend of Figure 1.
Results are expressed as the percentage of total apoptotic cells (early and late apoptotic cells). Values are means 6 sem (n= 3). * Significantly
different from sample incubated with LPS (p,0.05).
doi:10.1371/journal.pone.0026469.g004
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The lifespan of PMN increases significantly when these cells
migrate out of the circulation and into sites of inflammation, where
they encounter various pro-inflammatory mediators. Inappropri-
ate PMN survival and persistence at sites of inflammation and/or
excessive PMN activation lead to the release of cytotoxic contents
into the extracellular environment, a process that contributes to
many inflammatory disorders [49,50,51]. The ability of high
concentrations of IVIg to dampen PMN responses to pro-
inflammatory stimuli may thus contribute to the beneficial effect
of IVIg observed in autoimmune and inflammatory diseases,
adding to the long list of its non exclusive mechanisms of action [8]
[9]. Finally, the ability of IVIg to counteract the LPS-induced
delay in PMN apoptosis supports the use of IVIg in allergic
patients, and especially in asthma. In some asthma patients, in
whom the inflammation is non-atopic, non-IgE-dependent and
non-eosinophilic, it has been reported that airway neutrophilia,
related to delayed neutrophil apoptosis [16], correlates with
clinical severity [52]. These forms of asthma respond poorly to
corticosteroid therapy.
In conclusion, this study points to a differential effect of IVIg on
PMN, depending both on the IVIg concentration and the pro-
inflammatory environment. Low concentrations of IVIg induce
PMN activation and prolongation of lifespan, while high
concentrations counteract LPS-induced PMN activation. These
findings support the use of IVIg either as an antimicrobial or an
anti-inflammatory agent.
Materials and Methods
Therapeutic intravenous immunoglobulin
A therapeutic IVIg preparation (SandoglobulinH) was used for
all experiments, after extensive dialysis. F(ab9)2 fragments were
prepared from IVIg by pepsin digestion (2% wt/wt; Sigma, St
Louis MO) followed by chromatography on a protein A Sepharose
column (Pharmacia, Uppsala, Sweden). F(ab9)2 fragments were
shown to be free of intact IgG and Fc fragments by means of SDS-
PAGE and ELISA (not shown). Fc fragments were obtained from
Dr. M.-C. Bonnet, Pasteur Me´rieux Se´rums & Vaccins, Marcy
L’Etoile, France (Debre, 1993 #440). Anti-Siglec-9 antibodies
(Abs) were depleted from IVIg preparations by affinity chroma-
tography, as reported in [19].
Incubation of whole blood with IVIg
Fresh whole-blood samples were obtained, after written consent,
from healthy donors purchased from Hoˆpital Hoˆtel Dieu,
Etablissement Franc¸ais du Sang (EFS), Paris, France, after ethical
approval for the use of such material by the INSERM’s and EFS’s
ethic committees: convention 09/EFS/024. Samples were treated
at 37uC with PBS, HSA (1–25 mg/ml), IVIg (1–25 mg/ml) or
equimolar concentrations of F(ab9)2 or Fc fragments for various
periods of time. In some experiments, blood samples were first
incubated with IVIg or F(ab9)2 fragments and then stimulated with
LPS from E. coli serotype R515 (LPS, 10 ng/ml; Invivogen, San
Diego, CA).
Determination of adhesion molecule expression at the
PMN surface
After incubation with PBS, HSA or IVIg as described above,
samples were then stained at 4uC for 30 min with PE-anti-human
CD11b (Dakopatts, Glostrup, Denmark) or purified anti-L-selectin
(BD Biosciences, San Jose, CA). To study L-selectin expression,
samples were washed with ice-cold PBS and incubated at 4uC for
30 min with FITC-goat anti-mouse (Ab Nordic Immunology,
Tilburg, The Netherlands). Erythrocytes were lysed with FACS
lysing solution (BD Biosciences) and white blood cells were
resuspended in 1% paraformaldehyde–PBS. Nonspecific Ab
binding was determined on cells incubated with the same
concentration of an irrelevant Ab of the same isotype.
Measurement of the PMN oxidative burst
Superoxide anion (O2
2u) production was measured with a flow
cytometric assay derived from the hydroethidine (HE) oxidation
technique [26,53]. Whole-blood samples (500 ml) were loaded for
15 min with 1500 ng/ml HE (Fluka, Buchs, Switzerland) at 37uC
and then incubated with PBS, HSA or IVIg as described above.
Samples were then treated with PBS or 1026 M fMLP (Sigma
Chemical CO., St Louis, MO) for 5 min. Red cells were lysed as
described above and white cells were resuspended in 1%
paraformaldehyde-PBS.
Measurement of PMN apoptosis
Apoptosis of PMN in whole blood was quantified by using
annexin V and the impermeant nuclear dye 7-amino-actino-
mycin D (7-AAD) as previously described [26,54]. PMN
apoptosis was measured immediately after sampling or after
incubation in 24-well tissue culture plates at 37uC with PBS,
HSA or IVIg as described above. Cycloheximide (Calbiochem,
La Jolla, CA) (10 mg/ml) and LPS (10 ng/ml) were used as pro-
apoptotic and anti-apoptotic controls, respectively [26]. Whole-
blood samples (100 ml) were then washed twice in PBS,
incubated with APC-anti-CD15 for 15 min, and then incubated
with APC-annexin V for 15 minutes. After dilution in PBS
(500 ml), the samples were incubated with 7-AAD (BD
Biosciences) at room temperature for 15 minutes and analyzed
immediately by flow cytometry.
Flow cytometry
A Becton Dickinson LSRII flow cytometer was used. PMN
were analyzed with DIVA software. To measure apoptosis in
whole blood, PMN were identified as CD15high cells and 26105
events were counted per sample. A gate was drawn around the
PMN population (see Figure 2 Panel A). Fluorescence analysis
was performed on this gate (see Figure 2 Panel B). The
combination of FITC-annexin V and 7-AAD was used to
distinguish early apoptotic cells (annexin V+/7-AAD2), from late
apoptotic cells (annexin V+/7-AAD+), necrotic cells (annexin
V2/7-AAD+) and viable cells (unstained). In other experiments,
forward and side scatter were used to identify the PMN
population and to gate out other cells and debris; 10 000 events
were counted per sample.
Statistical analysis
Data are reported as means 6 SEM. Comparisons were based
on ANOVA and Tukey’s Post Hoc tests, using Prism 3.0 software
(Graph Pad software). Significance was assumed at p,0.05.
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